BioRealm has been selected by NVIDIA to be part of their Inception Program, designed to nurture "dedicated and exceptional startups who are revolutionizing industries with advances in AI and data science."

We are extremely honored to have been selected by NVIDIA and to receive such recognition by an industry giant that has played an extraordinary role in the renaissance of artificial intelligence.

NVIDIA's generous support will allow us to provide even more value to our clients, and we are excited to see what we can all create together.

About NVIDIA's Inception Program

Read more about the NVIDIA Inception Program.

Award Phase
2018 Biosignatures of Opioid Addiction Treatment Success Phase I
2018 Smokescreen Translational (TL) Analysis Platform Phase II
2016 Smokescreen Translational (TL) Analysis Platform Phase I
2015 Smokescreen: Genetic Screening Tool for Tobacco Dependence and Treatment Approaches Pop Mod Supplement Within Scope and Extension Phase II
2013 Smokescreen: Genetic Screening Tool for Tobacco Dependence and Treatment Approaches Phase II
2012 Smokescreen: Genetic Screening Tool for Tobacco Dependence and Treatment Approaches Phase I



"Because of the Smokescreen® array, we have the ability to reveal genetic information previously hidden in NIDA's samples. We have great confidence in Smokescreen® ‒ it is a validated platform that will become a crucial tool in advancing addiction research and moving the field towards personalized treatment."
— Dr. Andrew Brooks, RUCDR Infinite Biologics’ Chief Operating Officer and Director of Technology Development

About RUCDR Infinite Biologics

RUCDR Infinite Biologics offers a complete and integrated selection of biological sample processing, analysis and biorepository services to government agencies, academic institutions, foundations, and biotechnology and pharmaceutical companies within the global scientific community. RUCDR provides DNA, RNA, and cell lines with clinical data to hundreds of research laboratories for studies on mental health and developmental disorders, drug and alcohol abuse, diabetes and digestive, liver, and kidney diseases. A unit of Rutgers University’s Human Genetics Institute of New Jersey, RUCDR is the world’s largest university-based biorepository. In 2012, a Bioprocessing Solutions Alliance was created between RUCDR and BioStorage Technologies to provide research companies and organizations with a state-of-the-art scientific and technology infrastructure for the delivery of advanced sample bioprocessing and biobanking solutions. Read more at



“We are excited to be part of BioRealm’s vision of improving human health by providing insight into the genetics of tobacco-related illness. It was a pleasure to work with BioRealm’s team of dedicated scientists to co-develop this cutting-edge technology.”
— Dr. Frank R. Witney, President and Chief Executive Officer of Affymetrix

About Affymetrix

Affymetrix technologies enable multiplex and simultaneous analysis of biological systems at the cell, protein, and gene level, facilitating the rapid translation of bench-top research into clinical and routine use for human health and wellness. Affymetrix provides leadership and support, partnering with customers in pharmaceutical, diagnostic, and biotechnology companies, as well as leading academic, government, and non-profit research institutes in their quest to use biology for a better world. More than 2,300 microarray systems have been shipped around the world and more than 94,000 peer-reviewed papers have been published citing Affymetrix technologies. Affymetrix is headquartered in Santa Clara, California, and has manufacturing facilities in Cleveland, Ohio, San Diego, Vienna, and Singapore. Affymetrix has about 1,100 employees worldwide and maintains sales and distribution operations across Europe, Asia, and Latin America. For more information about Affymetrix, please visit